Evidence map›Paper›PMID 34952751›Full record

Trial reportVaccine2022

A randomized controlled trial of antibody response to 2019-20 cell-based inactivated and egg-based live attenuated influenza vaccines in children and young adults.

Katherine V Williams, Bo Zhai, John F Alcorn, Mary Patricia Nowalk, Min Z Levine, Sara S Kim, Brendan Flannery, Krissy Moehling Geffel, Amanda Jaber Merranko, Jennifer P Nagg and 5 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Katherine V WilliamsDepartment of Family Medicine, University of Pittsburgh, 4420 Bayard Street, Suite 520, Pittsburgh, PA 15260, USA. Electronic address: kvw3@pitt.edu.
Bo ZhaiDepartment of Immunology, University of Pittsburgh, 9127 Rangos Research Center, 4401 Penn Avenue, Pittsburgh, PA 15224 USA. Electronic address: bo.zhai@chp.edu.
John F AlcornDepartment of Immunology, University of Pittsburgh, 9127 Rangos Research Center, 4401 Penn Avenue, Pittsburgh, PA 15224 USA; Department of Pediatrics, University of Pittsburgh, 3520 Fifth Avenue, Pittsburgh, PA 15213, USA. Electronic address: John.Alcorn@chp.edu.
Mary Patricia NowalkDepartment of Family Medicine, University of Pittsburgh, 4420 Bayard Street, Suite 520, Pittsburgh, PA 15260, USA. Electronic address: tnowalk@pitt.edu.
Min Z LevineNational Center Immunizations and Respiratory Disease, Center for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: mwl2@cdc.gov.
Sara S KimNational Center Immunizations and Respiratory Disease, Center for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: omy1@cdc.gov.
Brendan FlanneryNational Center Immunizations and Respiratory Disease, Center for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: bif4@cdc.gov.
Krissy Moehling GeffelDepartment of Family Medicine, University of Pittsburgh, 4420 Bayard Street, Suite 520, Pittsburgh, PA 15260, USA. Electronic address: kkm17@pitt.edu.
Amanda Jaber MerrankoFalk Pharmacy, University of Pittsburgh Medical Center (UPMC), 3601 Fifth Avenue, Pittsburgh, PA 15213, USA. Electronic address: jabera@upmc.edu.
Jennifer P NaggDepartment of Pediatrics, University of Pittsburgh, 3520 Fifth Avenue, Pittsburgh, PA 15213, USA. Electronic address: Jennifer.Nagg@chp.edu.
Mark CollinsDepartment of Family Medicine, University of Pittsburgh, 4420 Bayard Street, Suite 520, Pittsburgh, PA 15260, USA. Electronic address: mjc@pitt.edu.
Michael SusickDepartment of Family Medicine, University of Pittsburgh, 4420 Bayard Street, Suite 520, Pittsburgh, PA 15260, USA. Electronic address: susickm@upmc.edu.
Karen S ClarkeDepartment of Family Medicine, University of Pittsburgh, 4420 Bayard Street, Suite 520, Pittsburgh, PA 15260, USA. Electronic address: KAC373@pitt.edu.
Richard K ZimmermanDepartment of Family Medicine, University of Pittsburgh, 4420 Bayard Street, Suite 520, Pittsburgh, PA 15260, USA. Electronic address: zimmrk@upmc.edu.
Judith M MartinDepartment of Pediatrics, University of Pittsburgh, 3520 Fifth Avenue, Pittsburgh, PA 15213, USA. Electronic address: martinju@pitt.edu.
University of Pittsburgh · USNational Center for Immunization and Respiratory Diseases · USUniversity of Pittsburgh Medical Center · US

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
Institutional Career Development CoreKL2TR001856 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RAY, KRISTIN N, RUBIO, DORIS M · 2016 to 2025
$13.8M
NRSA Training CoreTL1TR001858 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RADOMSKI, THOMAS, RUBIO, DORIS M · 2016 to 2025
$11.1M
Outpatient VE for seasonal flu, pandemic flu and RSV in a large, diverse networkU01IP001035 · IP · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZIMMERMAN, RICHARD K · 2016 to 2020
$7.8M
Pittsburgh Training Grant in Pediatric Pulmonary MedicineT32HL129949 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Juan Carlos Celedon · 2016 to 2026
$2.9M
ACL HHS U01IP001035NCATS NIH HHS KL2 TR001856NCATS NIH HHS TL1 TR001858NCATS NIH HHS UL1 TR001857NCIRD CDC HHS U01 IP001035NHLBI NIH HHS T32 HL129949
6 · The paper itself

Abstract

backgroundHemagglutination inhibition (HAI) titers to the live-attenuated influenza vaccine (LAIV4) are typically lower than its counterpart egg-based inactivated influenza vaccines (IIV). Similar comparisons have not been made between LAIV4 and the 4-strain, cell-culture inactivated influenza vaccine (ccIIV4). We compared healthy children's and young adults' HAI titers against the 2019-2020 LAIV4 and ccIIV4.

methodsParticipants aged 4-21 years were randomized 1:1 to receive ccIIV4 (n = 100) or LAIV4 (n = 98). Blood was drawn prevaccination and on day 28 (21-35) post vaccination. HAI assays against egg-grown A/H1N1, A/H3N2, both vaccine B strains and cell-grown A/H3N2 antigens were conducted. Primary outcomes were geometric mean titers (GMT) and geometric mean fold rise (GMFR) in titers.

resultsGMTs to A/H1N1, A/H3N2 and B/Victoria increased following both ccIIV and LAIV and to B/Yamagata following ccIIV (p < 0.05). The GMFR range was 2.4-3.0 times higher for ccIIV4 than for LAIV4 (p < 0.001). Within vaccine types, egg-grown A/H3N2 GMTs were higher (p < 0.05) than cell-grown GMTs [ccIIV4 day 28: egg = 205 (95% CI: 178-237); cell = 136 (95% CI:113-165); LAIV4 day 28: egg = 96 (95% CI: 83-112); cell = 63 (95% CI: 58-74)]. The GMFR to A/H3N2 cell-grown and egg-grown antigens were similar. Pre-vaccination titers inversely predicted GMFR.

conclusionThe HAI response to ccIIV4 was greater than LAIV4 in this study of mostly older children, and day 0 HAI titers inversely predicted GMFR for both vaccines. Lower prevaccination titers were associated with greater GMFR in both vaccine groups.

Indexed as

Influenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesAdolescentAntibodies, ViralAntibody FormationChildHemagglutination Inhibition TestsHumansInfluenza A Virus, H3N2 SubtypeVaccines, AttenuatedVaccines, InactivatedYoung AdultAntibodies, ViralInfluenza VaccinesVaccines, AttenuatedVaccines, InactivatedCell-culture-based inactivated influenza vaccineEgg-based live attenuated influenza vaccineHemagglutination inhibition assayInfluenzaInfluenza vaccineRandomized controlled trial

Identifiers

PMID34952751
PMCPMC8803136
OpenAlexW4226262500

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.